For patients with neuromyelitis optica spectrum disorder (NMOSD), the body is effectively at war with itself. The immune system targets the spinal cord and optic nerves, triggering cycles of debilitating pain, vision loss, and paralysis. For two individuals, that war ended over a decade ago with a single, high-stakes medical intervention.

Fifteen years after receiving an allogeneic hematopoietic stem-cell transplant, both patients remain entirely free of disease symptoms. The findings, published in the journal Med, offer a rare glimpse into the potential for a functional cure in severe autoimmune conditions.

The Reset Button for the Immune System

NMOSD is notoriously difficult to manage. While standard medications can suppress symptoms, they often fail to halt the underlying autoimmune destruction. In this study, researchers attempted a more radical approach: replacing the patients' immune systems entirely.

Before the transplant, the patients underwent a rigorous conditioning regimen using chemotherapy drugs—fludarabine and treosulfan—alongside monoclonal antibodies. This process was designed to clear out the B cells responsible for producing the harmful antibodies that attack the nervous system. Once the "faulty" immune system was suppressed, donor stem cells were infused to rebuild a healthy, non-reactive immune response.

One patient received cells from his sister in 2009, while the second patient received a transplant from an unrelated donor in 2010. The results were transformative. The male patient regained neurological function and went on to start a family, while the female patient saw significant improvement in motor function and was able to discontinue all disease-modifying medications.

Why Caution Remains the Standard

While the 15-year milestone is remarkable, the medical community is not yet calling this a standard of care. The procedure is inherently aggressive and carries significant risks, including secondary cancers and life-threatening infections, which remain the second leading cause of death associated with this type of transplant.

Furthermore, the study size is limited to just two individuals. Experts emphasize that the difficulty of finding compatible donors and the potential for graft-versus-host disease—where donor cells attack the patient’s healthy tissue—make this a treatment of last resort. For now, researchers suggest the procedure should be reserved for younger patients who have exhausted all other therapeutic options.

What Experts Say

"The durability of the response is what makes this case so compelling," said one independent researcher familiar with the study. "However, we are talking about a highly invasive procedure. We need to see if this level of success can be replicated in larger, more diverse cohorts before we can consider this a viable pathway for the broader NMOSD population."

Key Takeaways

  • Two patients with NMOSD have remained symptom-free for 15 years following a single allogeneic hematopoietic stem-cell transplant.
  • The procedure effectively replaced the patients' immune systems, eliminating the production of the harmful antibodies that cause nerve damage.
  • Due to the high risk of secondary complications and infection, the treatment is currently viewed only as an option for patients who do not respond to standard therapies.

Researchers are now looking toward the next phase of investigation. The primary challenge will be determining whether less-toxic conditioning regimens can achieve the same immune-reset effect without the severe side effects observed in traditional transplant protocols. As clinical teams prepare for larger trials, the focus will shift to identifying which specific patient profiles are most likely to benefit from this high-risk, high-reward intervention.

This article is for informational purposes only. Always consult a qualified healthcare professional before making any medical decisions.